Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain

References

• Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. Fontana-on-Lake (WI); 2020.
   Google Scholar
• Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy. 2004;59(5):469–478.
   PubMed Web of Science ®Google Scholar
• Global surveillance, prevention and control of chronic respiratory diseases. A comprenhensive approach. Geneva: Switzerland; 2007.
   Google Scholar
• Melero Moreno C, Quirce S, Huerta A, et al. Economic impact of severe asthma in Spain: multicentre observational longitudinal study. J Asthma. 2019(8);56:861–871.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373.
   PubMed Web of Science ®Google Scholar
• Puig-Junoy J, Pascual-Argenté N. Socioeconomic costs of asthma in the European Union, United States and Canada: a systematic review. Rev Esp Salud Publica. 2017;91:e201703025.
   PubMed Web of Science ®Google Scholar
• Souliotis K, Kousoulakou H, Hillas G, et al. Direct and indirect costs of asthma management in Greece: an expert panel approach. Front Public Heal. 2017;5:67.
   PubMed Web of Science ®Google Scholar
• Skolnik NS, Carnahan SP. Primary care of asthma: new options for severe eosinophilic asthma. Curr Med Res Opin. 2019;35(7):1309–1318.
   PubMed Web of Science ®Google Scholar
• Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J Clin Med. 2019;8:1375.
   PubMed Web of Science ®Google Scholar
• Busse W, Chupp G, Nagase H, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200.e20.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Pocket guide for asthma management and prevention for adults and children older than 5 years old. A pocket guide for health professional updated 2019. Fontana-on-Lake (WI); 2019.
   Google Scholar
• Buhl R, Humbert M, Bjermer L, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49(5):1700634.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European Medicines Agency. Assessment report on extension(s) of marketing authorisation. Nucala. Procedure No. EMEA/H/C/003860/X/0018. [Internet]. 2019. Available from: https://bit.ly/37aRrJh. 2015.
   Google Scholar
• European Medicines Agency. Cinqaero: EPAR – product information. 2016.
   Google Scholar
• European Medicines Agency. Fasenra: EPAR – product information. 2018.
   Google Scholar
• Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918–927.
   PubMed Web of Science ®Google Scholar
• Cabon Y, Molinari N, Marin G, et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47(1):129–138.
   PubMed Web of Science ®Google Scholar
• Waljee AK, Rogers MAM, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.
   PubMed Web of Science ®Google Scholar
• Bloechliger M, Reinau D, Spoendlin J, et al. Adverse events profile of oral corticosteroids among asthma patients in the UK: Cohort study with a nested case-control analysis. Respir Res. 2018;19(1):75.
   PubMed Web of Science ®Google Scholar
• Sociedad Española de Neumología y Cirugía Torácica. GEMA 5.0. Guía española para el manejo del asma. 2020.
   Google Scholar
• Agencia Española de Medicamentos y Productos Sanitarios M de S. Informe de posicionamiento terapéutico de benralizumab (Fasenra®) como tratamiento adicional en el asma grave no controlada eosinofílica [Internet]. 2019. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-benralizumab-Fasenra-asma_EPOC.pdf?x74012.
   Google Scholar
• Agencia Española de Medicamentos y Productos Sanitarios M de S. Informe de posicionamiento terapéutico de reslizumab (Cinqaero®) como tratamiento adicional en el asma eosinofílica grave no controlada [Internet]. 2018. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-reslizumab-Cinqaero-asma_EPOC.pdf?x42633.
   Google Scholar
• Agencia Española de Medicamentos y Productos Sanitarios M de S. Informe de posicionamiento terapéutico de mepolizumab (Nucala®) como tratamiento adicional en el asma eosinofílica refractaria grave [Internet]. 2016. Available from: https://www.aemps.gob.es/va/medicamentosUsoHumano/informesPublicos/docs/IPT-mepolizumab-Nucala-asma_EPOC.pdf.
   Google Scholar
• Henriksen DP, Bodtger U, Sidenius K, et al. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis. Eur Clin Respir J. 2018;5(1):1536097.
   PubMed Web of Science ®Google Scholar
• Cockle SM, Stynes G, Gunsoy NB, et al. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison. Respir Med. 2017;123:140–148.
   PubMed Web of Science ®Google Scholar
• McQueen RB, Sheehan DN, Whittington MD, et al. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 2018;36(8):957–971.
   PubMed Web of Science ®Google Scholar
• López-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11(5):513–520.
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Del Llano J, et al. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 2002;16(4):334–343.
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. Mepolizumab for treating severe refractory eosinophilic asthma. Technology appraisal guidance [TA431]. 2017.
   Google Scholar
• Quirce S, Melero C, Huerta A, et al. Economic impact of severe asthma exacerbations in Spain: multicentre observational study. J Asthma. 2021;58(2):207–212.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MDC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836.
   PubMed Web of Science ®Google Scholar
• Watson L, Turk F, James P, et al. Factors associated with mortality after an asthma admission: a national United Kingdom database analysis. Respir Med. 2007;101(8):1659–1664.
   PubMed Web of Science ®Google Scholar
• Levy ML. The national review of asthma deaths: what did we learn and what needs to change? Breathe. 2015;11(1):14–24.
   Web of Science ®Google Scholar
• Instituto Nacional de Estadística (INE). Population mortality tables for Spain by year, province, sex, age, and functions. 2018.
   Google Scholar
• Base de Datos de Medicamentos. Consejo General de Colegios Oficiales de Farmacéuticos [WWW Document]. n.d.
   Google Scholar
• Ministerio de Sanidad C y BSG de E. Registro de Actividad de Atención Especializada, Conjunto Mínimo Básico de Datos [WWW Document]. [cited 2020 Aug 4]. Available from: https://pestadistico.inteligenciadegestion.mscbs.es/publicoSNS/comun/ArbolNodos.aspx?idNodo=23606
   Google Scholar
• Gisbert R, Brosa M. Health costs and cost-effectiveness ratios database: eSalud. Barcelona: Oblikue Consulting, S.L.; 2007.
   Google Scholar
• Crespo C, Brosa M, Soria-Juan A, et al. Direct cost of diabetes mellitus and its complications in Spain (SECCAID Study: Spain estimated cost Ciberdem-Cabimer in Diabetes). Av en Diabetol. 2013;29(6):182–189.
   Google Scholar
• ANEXO I Ficha Técnica o Resumen de las Características del producto, Nucala. FT_1151043001. European Medicines Agency.
   Google Scholar
• ANEXO I Ficha Técnica o Resumen de las Características del producto, Fasenra. FT_1171252001. European Medicines Agency.
   Google Scholar
• ANEXO I Ficha Técnica o resumen de las características del producto, Cinqaero. FT_1161125001. European Medicines Agency.
   Google Scholar
• Sicras-Mainar A, Capel M, Navarro-Artieda R, et al. Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain. J Med Econ. 2020;23(5):492–500.
   PubMed Web of Science ®Google Scholar
• SIRIUS Statistical Report, Data on file. n.d.
   Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2015.
   Google Scholar
• Edmonds M, Milan S, Camargo CJ, et al. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2012;12:CD002308.
   PubMedGoogle Scholar
• Starkie HJ, Briggs AH, Chambers MG, et al. Predicting EQ-5D values using the SGRQ. Value Health. 2011;14(2):354–360.
   PubMed Web of Science ®Google Scholar
• Chupp G, Bradford E, Albers F, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22–27.
   PubMedGoogle Scholar
• Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D Scores for the United Kingdom. Med Decis Making. 2011;31(6):800–804.
   PubMed Web of Science ®Google Scholar
• Chisholm D, Evans DB. Economic evaluation in health: saving money or improving care? J Med Econ. 2007;10(3):325–337.
   Google Scholar
• Bodrogi J, Kaló Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol. 2010;159(7):1367–1373.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
   Google Scholar
• OECD. Health at a glance 2019: OECD indicators. Paris: OECD Publishing; 2019.
   Google Scholar
• Llanos J-P, Ortega H, Bogart M, et al. Real-world effectiveness of Mepolizumab in patients with severe asthma: an examination of exacerbations and costs. JAA. 2020;13:77–87.
   Web of Science ®Google Scholar
• Ilic AD, Zugic V, Zvezdin B, et al. Influence of inhaler technique on asthma and COPD control: a multicenter experience. COPD. 2016;11:2509–2517.
   Google Scholar
• European Medicines Agency. Assessment report on extension(s) of marketing authorisation. Nucala. Procedure No. EMEA/H/C/003860/X/0018; 2019.
   Google Scholar